Shedding Light on How Tumors Become Resistant to Immunotherapy – Technology Networks
Technology Networks |
Shedding Light on How Tumors Become Resistant to Immunotherapy
Technology Networks In tumor immunotherapy, the body’s own defense system is activated against the tumor cells. However, for the majority of patients, the tumor cells become resistant to the treatments used. Researchers at the University of Zurich and the University … |
Technology Networks |
Shedding Light on How Tumors Become Resistant to Immunotherapy
Technology Networks In tumor immunotherapy, the body’s own defense system is activated against the tumor cells. However, for the majority of patients, the tumor cells become resistant to the treatments used. Researchers at the University of Zurich and the University … |
High Point Observer |
Controversial CRISPR paper earns second editorial note
Retraction Watch (blog) When “Unexpected mutations after CRISPR–Cas9 editing in vivo” was published May 30, it immediately drew criticism from many of the top scientists working with CRISPR, including those associated with companies seeking to develop CRISPR-based … $-0.42 EPS Expected for Intellia Therapeutics (NTLA), Colony Financial (CLNY) Sentiment Is 0.92High Point Observer The Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Consensus Rating of “Buy” by AnalystsBangaloreWeekly |
High Point Observer |
Controversial CRISPR paper earns second editorial note …
Retraction Watch (blog) Against the authors’ objections, Nature Methods has added an expression of concern to a 2017 paper that drew fire for suggesting a common gene editing … $-0.42 EPS Expected for Intellia Therapeutics (NTLA), Colony …High Point Observer Intellia Therapeutics (NTLA) Reaches $17.68 After 3.00% Up Move …HuronReport -$0.42 EPS Expected for Intellia Therapeutics, Inc. (NASDAQ:NTLA …Sports Perspectives BangaloreWeekly all 5 news articles » |
FierceBiotech |
US CRISPR rights battle heats up as UC team launches appeal
FierceBiotech Last year, the U.S. Patent and Trademark Office (USPTO) started an investigation into whose claim for the patent on using CRISPR-Cas9 to edit genes is stronger—and so determine who profits from CRISPR in the coming years. That culminated in a win for … |
Science Magazine |
Ding, ding, ding! CRISPR patent fight enters next round
Science Magazine The UC litigants indisputably first showed in 2012 that CRISPR could work in DNA of simpler organisms, and soon after filed a patent application on the gene-editing technique. They claim the Broad group learned from that disclosed invention and applied … US CRISPR rights battle heats up as UC team launches appealFierceBiotech UC and Partners File Brief in Appeal of PTAB CRISPR DecisionGenetic Engineering & Biotechnology News (press release) CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences …Nasdaq |